Bolt Posts First Post-Merger Quarter: $120M PIPE Extends Runway Into 2028, PRA-216 Phase 2 Underway
BOLT sits 91% above its 52-week low of $3.1.
Summary
Bolt's first quarter as a combined company shows the $120 million Prana-era raise pushing cash runway into 2028, with PRA-216 Phase 2 studies now enrolling and initial data expected in 2Q 2027.
Key Events · Earnings and Guidance · BOLT
-
Runway Extended Into 2028
The October $120.0 million gross private placement is expected to fund operations into 2028, replacing the prior 10-Q warning that the company might not survive beyond Q1 2027 without new funding.
-
Q3 Loss Narrows Sharply
Net loss was $4.4 million for Q3 2026 versus $7.1 million a year earlier; R&D fell to $2.2 million from $6.5 million and G&A to $2.5 million from $3.3 million after restructuring. Collaboration revenue was zero versus $2.2 million.
-
PRA-216 Phase 2 Studies Started
Phase 2 trials are underway in asthma, atopic dermatitis and COPD, with a fourth planned in eosinophilic esophagitis; patient proof-of-concept data across all four is expected beginning 2Q 2027.
-
Share Count Set at ~34.2M
After the Prana acquisition and private placement, Bolt expects approximately 34.2 million common shares outstanding on an as-converted basis, before PIPE warrant exercises, subject to stockholder approval of the Series D conversion.
Analysis · BOLT · Life Sciences
This is the first look at Bolt as a combined company after the Prana reverse merger and $120 million private placement closed in October. The cash position at September 30 ($14.8 million) predates the raise, so the meaningful number is the runway: management now says funding carries into 2028, versus the prior 10-Q warning that the company might not survive past Q1 2027 without new money. That removes the near-term financing overhang that dominated the story. The other new item is execution: PRA-216 Phase 2 studies are now running in asthma, atopic dermatitis and COPD, with patient proof-of-concept data expected from 2Q 2027 across four studies. The offset is dilution already incurred — roughly 34.2 million shares on an as-converted basis after the deal and PIPE, before warrant exercises, against about 1.97 million weighted-average shares in the quarter. Stockholder approval to convert the Series D preferred is the next gating item, and ASC 805 purchase accounting disclosures are due by January 8, 2027.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BOLT was trading at $5.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $3.10 to $7.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.